Agency: National Institutes of Health (NIH) Role: 18th Director of the National Institutes of Health (April 2025–present); also serving as Acting CDC Director (February 2026–present) Severity: P1 — Documented pattern of conduct that materially advanced erosion of public health infrastructure Party/Affiliation: Republican-aligned; Make America Healthy Again Commission

Bio and Background

Education

• B.A. in Economics, Stanford University
• M.D., Stanford University School of Medicine
• Ph.D. in Economics, Stanford University[1]

Pre-Government Career

Bhattacharya held a tenured professorship in health policy at Stanford University School of Medicine and was a research associate at the National Bureau of Economic Research. His academic work focused on the economics of health care, with 161 scholarly articles published in peer-reviewed journals in medicine, economics, health policy, epidemiology, and statistics.[1][2]

COVID-19 Prominence

Bhattacharya rose to national prominence during the COVID-19 pandemic as a vocal critic of lockdowns, school closures, and mask mandates. In October 2020, he co-authored the Great Barrington Declaration with Martin Kulldorff (Harvard) and Sunetra Gupta (Oxford), which advocated for “focused protection” of vulnerable populations while allowing the virus to spread among lower-risk groups to achieve herd immunity.[3][4]

The Great Barrington Declaration was criticized by the World Health Organization, the director of the NIH at the time (Francis Collins), and numerous public health experts as dangerous and impractical. Collins privately emailed Anthony Fauci calling the authors “fringe epidemiologists” and requested a “quick and devastating published takedown.”[3][5]

In April 2020, Bhattacharya co-authored a seroprevalence study in Santa Clara County that estimated COVID-19 infection rates were 50–85 times higher than reported, suggesting a much lower fatality rate. The study drew criticism for recruitment methods, statistical errors, and undisclosed funding from JetBlue founder David Neeleman.[4][6]

In February 2021, Bhattacharya predicted in a Wall Street Journal op-ed that COVID would be “mostly gone by April” 2021. Subsequent Delta and Omicron variant surges resulted in hundreds of thousands of additional deaths.[6]

Murthy v. Missouri

Bhattacharya was a plaintiff in Murthy v. Missouri (formerly Missouri v. Biden), which alleged that federal officials had pressured social media companies to suppress speech critical of government COVID-19 policies. The Supreme Court ruled 6-3 in June 2024 that the plaintiffs lacked standing to bring the claim.[3]

Role and Function

The NIH is the nation’s medical research agency and the largest funder of biomedical research in the world, with a budget exceeding $47 billion (FY2024) and approximately 27 institutes and centers. NIH funds research conducted at universities, medical schools, and research institutions across the country and internationally.[7]

As Director, Bhattacharya oversees NIH’s research portfolio and is responsible for aligning the agency’s activities with the Make America Healthy Again Commission established by executive order in February 2025. He has stated his priorities include combating the chronic disease crisis (cancer, heart disease, diabetes, obesity), fostering “gold standard” research, and modernizing biosafety oversight.[7][8]

Since February 2026, Bhattacharya has simultaneously served as Acting Director of the CDC after the departure of Acting CDC Director Jim O’Neill, making him responsible for both of the nation’s principal health research and disease prevention agencies.[9]

Documented Actions

NIH Research Grant Terminations

Action: Between February and August 2025, thousands of NIH research grants were terminated or frozen, disrupting 383 clinical trials and affecting more than 74,000 enrolled participants.

Date: February–August 2025

Evidence: A peer-reviewed study published in JAMA Internal Medicine (Harvard Medical School researchers) found that of 11,008 NIH-funded clinical trials active during this period, 383 (3.5%) lost grant funding. Among affected trials: 134 were actively recruiting patients, 43 had participants receiving interventions, and infectious disease trials were disproportionately impacted (14.4% terminated). The study noted that “unanticipated funding disruptions raise concerns about avoidable waste, data quality, and compromised ethical obligations to participants.”[10][11]

Bhattacharya’s response: Testified before the Senate HELP Committee (February 2026) and Senate Appropriations Subcommittee (May 2026) that “at most, something like a dozen clinical trials actually were terminated,” characterizing the JAMA findings as “inaccurate” and stating that many disrupted grants were “renegotiated and restarted.” He did not provide evidence to support his lower figure when pressed by senators.[12][13]

Congressional response: Senator Ed Markey (D-MA) and the Massachusetts congressional delegation formally demanded documentation of all terminated grants, the number of disrupted clinical trials and affected patients, and “a detailed explanation of the methodology and data underlying the Director’s testimony that only ‘a dozen’ clinical trials were disrupted.”[12]

NIH Workforce Reduction

Action: The NIH workforce was reduced from approximately 21,000 employees to 17,300 — a loss of approximately 3,700 employees including 1,100 doctoral scientists.

Date: 2025–2026

Evidence: Senator Tim Kaine (D-VA) reported at a Senate HELP Committee hearing that the NIH workforce had shrunk from 21,000 to 17,300 employees, including the loss of 1,100 doctoral scientists. Grantees reported delays and communication challenges resulting from the workforce reduction.[14]

Senator Susan Collins (R-ME) warned that the cuts “impact early career scientists” and that “competing countries are actively recruiting American talent.”[14]

NIAID Restructuring and Leadership Turnover

Action: Redirected the National Institute of Allergy and Infectious Diseases (NIAID) away from civilian biodefense, reassigned senior leaders, and presided over leadership vacancies across NIH.

Date: April 2025–present

Evidence: Bhattacharya confirmed to the Senate that NIAID was being redirected away from civilian biodefense and toward infectious diseases, allergy, and immunology. Multiple senior NIAID officials departed or were reassigned, including Acting Director Jeffery Taubenberger, who resigned in May 2026. Senators Tammy Baldwin and Patty Murray expressed concern about “leadership gaps during the Ebola outbreak in the Democratic Republic of Congo and ongoing hantavirus monitoring efforts.”[15][16]

Senator Patty Murray noted that many NIH institutes and centers were operating under interim leadership and advisory council member positions were not being filled. Bhattacharya acknowledged the need to “promptly fill these leadership positions.”[14]

Proposed Budget Cuts

Action: Supported or did not oppose the administration’s proposed $5–6 billion cut to the NIH budget and a 15% cap on indirect research costs.

Date: 2025–2026

Evidence: The White House proposed reducing NIH funding by roughly $5 billion in its FY2027 budget request. When asked whether he supported the proposed $6 billion cut, Bhattacharya stated his role is to ensure “colleagues have the resources they need to fund the best biomedical research in this country” and that he is “grateful to work with Congress and the administration to make sure that’s possible” — without explicitly endorsing or opposing the cuts.[15]

Senator Collins pressed Bhattacharya on a proposed 15% cap on indirect research costs, warning it would “negatively affect cutting-edge research happening at universities, nonprofit laboratories, medical centers around the country.” Congress had blocked a similar proposal the prior year.[15]

Unified Strategy and Research Reprioritization

Action: Issued a Unified Strategy document reprioritizing NIH research toward chronic disease, consolidating peer review, creating an office to address replication crises, and establishing new foreign collaboration award structures.

Date: 2025–2026

Evidence: Bhattacharya published a strategy document directing NIH to prioritize research on cancer, heart disease, diabetes, and obesity in alignment with the Make America Healthy Again Commission. New policies included consolidating peer review, restricting foreign funding through an independent award tracking system, and modernizing data infrastructure.[7][14]

Controversies

Great Barrington Declaration

The Great Barrington Declaration (October 2020), which Bhattacharya co-authored, proposed allowing COVID-19 to spread freely among lower-risk populations while pursuing “focused protection” of vulnerable groups. The WHO called this approach “scientifically and ethically problematic.” Critics noted that the declaration did not account for long COVID, the burden on healthcare systems, or the practical impossibility of isolating only vulnerable populations. The declaration was funded in part by the American Institute for Economic Research, a libertarian think tank.[3][4][5]

Santa Clara Seroprevalence Study Criticism

Bhattacharya’s April 2020 seroprevalence study in Santa Clara County was criticized for methodological flaws including biased recruitment (participants were recruited through social media and community contacts, including by Bhattacharya’s wife), false claims that the test used was “FDA-approved,” and undisclosed funding from JetBlue founder David Neeleman.[4][6]

Disputed Pandemic Predictions

In February 2021, Bhattacharya predicted in the Wall Street Journal that COVID-19 would be “mostly gone by April.” The U.S. death toll stood at approximately 560,000 in April 2021, with an additional 650,000 deaths to follow from subsequent variant surges.[6]

Dual Leadership of NIH and CDC

Since February 2026, Bhattacharya has served as both NIH Director and Acting CDC Director, an unprecedented consolidation of leadership over the nation’s two principal public health agencies. Former CDC officials have expressed concern about a single official leading both agencies during active disease outbreaks.[9][17]

Public Health Impact Assessment

Research Disruption

The termination of hundreds of NIH grants has disrupted clinical trials studying treatments for cancer, infectious diseases, and behavioral health interventions, with more than 74,000 enrolled participants affected. A JAMA Internal Medicine commentary called the terminations an “unacceptable and unethical” risk to patients, noting that some participants “may be harmed by” loss of follow-up and monitoring.[10][11]

Brain Drain

The loss of 3,700 NIH employees including 1,100 doctoral scientists represents a significant erosion of U.S. biomedical research capacity. Senator Collins warned that competing nations were actively recruiting displaced American scientists.[14]

Infectious Disease Preparedness

The restructuring of NIAID away from civilian biodefense and the departure of senior infectious disease leaders occurred during active Ebola and hantavirus response efforts, raising concerns about the nation’s preparedness for emerging infectious disease threats.[15][16]

Institutional Credibility

Congressional testimony in which Bhattacharya disputed peer-reviewed findings from JAMA Internal Medicine without providing supporting evidence has contributed to concerns about the scientific credibility of NIH leadership.[12][13]

Truth and Reconciliation Considerations

• Mission subversion: Documenting whether NIH’s statutory research mission was subordinated to ideological priorities under the Make America Healthy Again agenda
• Scientific integrity: Assessing the long-term damage to the U.S. biomedical research enterprise from workforce reductions, grant terminations, and the departure of senior scientists
• Institutional capture: Examining the appointment of a figure known primarily for opposing mainstream public health consensus to lead the nation’s premier medical research agency
• Clinical trial ethics: Investigating the ethical obligations to the 74,000+ participants in clinical trials disrupted by grant terminations, including whether continuity of care was maintained
• Dual agency leadership: Evaluating the appropriateness and consequences of a single official simultaneously leading both NIH and CDC